Literature DB >> 8831663

A hammerhead ribozyme that cleaves perforin and fas-ligand RNAs in vitro.

Z Du1, C Ricordi, E Podack, R L Pastori.   

Abstract

Polyfunctional ribozymes targeting more than one RNA might be ideal for treatment of diseases caused by the expression of more than one mRNA. This is the case of Graft versus Host Disease, which in the mouse model is due to the action of two proteins responsible for different lytic pathways: perforin and fasligand. We have created a bifunctional ribozyme fusing two antiperforin and antifas-ligand hammerhead ribozymes with a stretch of CA dinucleotides. This bifunctional ribozyme is able to recognize and cleave in vitro perforin and fas-ligand mRNA in a specific and selective fashion, with a catalytic efficiency similar to that of its individual components.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8831663     DOI: 10.1006/bbrc.1996.1401

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  3 in total

1.  Perforin/granzyme-dependent and independent mechanisms are both important for the development of graft-versus-host disease after murine bone marrow transplantation.

Authors:  T A Graubert; J F DiPersio; J H Russell; T J Ley
Journal:  J Clin Invest       Date:  1997-08-15       Impact factor: 14.808

2.  Use of ribozymes and antisense oligodeoxynucleotides to investigate mechanisms of drug resistance.

Authors:  D Byrne; C Daly; R Nicamhlaoibh; A Howlett; K Scanlon; M Clynes
Journal:  Cytotechnology       Date:  1998-09       Impact factor: 2.058

3.  Down-regulation of Fas-L in glioma cells by ribozyme reduces cell apoptosis, tumour-infiltrating cells, and liver damage but accelerates tumour formation in nude mice.

Authors:  C C Chio; Y S Wang; Y L Chen; S J Lin; B C Yang
Journal:  Br J Cancer       Date:  2001-10-19       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.